Psychotropic Drug Use in Psychiatric Inpatients: Recent Trends and Changes over Time-Data from the AMSP Study

A considerable number of new drugs were introduced over the last few years. In this report we analyze to what extent they have come to be used in clinical practice and what changes in drug use have resulted from the availability of the new compounds.

For this purpose, data on drug use in 1995 and 2001 assessed at two reference days per year and per hospital within the drug safety program AMSP were compared for 10 hospitals that had been participating in both years. Atypical neuroleptics (NL) were used in 59.9 % of patients on NLs in 2001 (16.7 % in 1995), most frequently olanzapine, risperidone, clozapine, and quetiapine, in this order. Thirty-nine percent of patients still received typical NLs in antipsychotic indication (77.1 % in 1995), and 30.8 % received typical hypnosedative NLs (38.1 % in 1995). SSRIs, other new ADs, and TCAs were used in similar rates in 2001, i. e., in 40.5 %, 37.9 %, and 34.8 % of AD patients, respectively (1995 : 24.2 %, 6.2 %, and 72.3 %, respectively). Mirtazapine was the most common AD in 2001, followed by citalopram, sertraline, and doxepin.

Hypnotics were prescribed more frequently in 2001 (17.6 % vs. 11.7 %), mostly BZD agonists at that time, whereas overall anxiolytic use (in approximately 30 %) hardly changed over time. Mood stabilizers and anti-dementia drugs were given comparatively rarely, even in pertinent diagnoses. Polypharmacy was observed in about three-quarters of patients on psychotropic drugs, with a trend towards increasing use over time. Combinations of two NLs, of NL + AD, and of NLs + anxiolytic were most common in both years. Twenty percent of patients on atypical NLs received typical antipsychotic NLs additionally; typical hypnosedative NLs were used along with typical antipsychotics and atypical NLs in 20 % and 22 % of patients, respectively. TCAs and either SSRIs or other new ADs were still the most common AD combinations in 2001. Data were also analyzed according to the main diagnostic categories.

References

• 1 Barbui C, Danese A, Guaiana G, Mapelli L, Miele L, Monzani E, Perdudani M. Prescribing Second-Generation Antipsychotics and the Evolving Standard of Care in Italy.  Pharmacopsychiatry. 2002;  35 239-243
• 2 Bender S, Grohmann R, Rüther E. Adverse drug reactions in psychiatric in-patients treated with neuroleptics.  Pharmacopsychiatry. 2004;  37 Suppl 1 S46-53
• 3 Centorrino F, Eakin M, Bahk W -M, Kelleher J P, Pharm J, Salvatore P, Egil S, Baldessarini R. Inpatient Antipsychotic Drug Use in 1998, 1993, and 1989.  Am J Psychiatry. 2002;  159 1932
• 4 Ereshefsky L, Pharm D. Pharmacologic and Pharmacokinetic Considerations in Choosing an Antipsychotic.  J Clin Psychiat. 1999;  60 (suppl 10) 20-30
• 5 Freudenreich O, Goff C . Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.  Acta Psychiatr Scand. 2002;  106 323-330
• 6 Frye M, Ketter T, Leverich G, Huggins T, Lantz C, Denicoff K, Post R. The Increasing Use of Polypharmacotherapy for Refractory Mood Disorders: 22 Years of Study.  J Clin Psychiatry. 2000;  61/1 9-15
• 7 Grohmann R, Rüther E, Schmidt LG [ Ed.]. Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMÜP-Studie. Springer Berlin, Heidelberg, New York; 1994
• 8 Grohmann R, Rüther E, Engel R R, Hippius H. Assessment of Adverse Drug Reactions in Psychiatric Inpatients with the AMSP Drug Safety Program: Methods and First Results for Tricyclic Antidepressants and SSRI.  Pharmacopsychiatry. 1999;  32 21-28
• 9 Grohmann R, Hippius H, Helmchen H, Rüther E, Schmidt L G. The AMÜP study for drug surveillance in psychiatry - a summary of inpatient data.  Pharmacopsychiatry. 2004;  37 Suppl 1 S16-26
• 10 Italian Collaborative Study Group on the Outcome of Severe Mental D isorders. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy.  Eur J Clin Pharmacol. 1999;  55 685-690
• 11 Kropp S, Ziegenbein M, Grohmann R, Degner D. Galactorrhea Due to Psychotropic Drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S84-88
• 12 Leslie D, Rosenheck R. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.  Am J Psychiatry. 2002;  159/9 1534-1540
• 13 Levine J, Chengappa K NR, Brar J S, Gershon S, Yablonsky E, Stapf D, Kupfer D J. Psychotropic drug prescription patterns among patients with bipolar I disorder.  Bipolar Disord. 2000;  2 120-130
• 14 Linden M, Thiels C. Epidemiology of prescriptions for neuroleptic drugs: tranquilizers rather than antipsychotics.  Pharmacopsychiatry. 2001;  34 150-154
• 15 Lippert E, Aigner J M, Grohmann R, Klein H E, Schmauß M, Rüther E. Anwendungshäufigkeiten und Dosierungen von Psychopharmaka an psychiatrischen Versorgungskrankenhäusern. Ergebnisse aus dem Arzneimittelüberwachungsprojekt Bayern.  Psychopharmakotherapie. 1996;  3 178-183
• 16 McManus P, Mant A, Mitchell P B, Montgomery W S, Marley J, Auland M E. Recent trends in the use of antidepressant drugs in Australia, 1990 - 1998.  Med J Aust. 2000;  173 458-461
• 17 McManus P, Mant A, Mitchell P, Birkett D, Dudley J. Co-prescribing of SSRI’s and TCAs in Australia: how often does it occur and who is doing it?.  Br J Clin Pharmacol. 2001;  51 93-98
• 18 Nelson C. Combined Treatment strategies in psychiatry.  J Clin Psychiatry. 1993;  54 (Suppl. 9) 42-49
• 19 Pincus H A, Tanielian T L, Marcus S C, Olfson M, Zarin D A, Thompson J, Magno Zito J. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.  J Am Med Assoc. 1998;  279 526-531
• 20 Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics.  Eur Psychiatry. 1999;  14 33-40
• 21 Stahl S M. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.  J Clin Psychiatry. 1999;  60 (Suppl. 10) 31-41
• 22 Stahl S M. Antipsychotic polypharmacy, Part 2: tips on use and misuse.  J Clin Psychiatry. 1999;  60 506-507
• 23 Stahl S M. Antipsychotic polypharmacy: squandering precious resources?.  J Clin Psychiatry. 2002;  63 93-94
• 24 Stübner S, Rustenbeck E, Grohmann R, Wagner G, Engel R R, Neundörfer G, Möller H -J, Hippius H, Rüther E. Severe and Uncommon Involuntary Movement Disorders due to Psychotropic Drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S54-64
• 25 Takei N, Inagaki A. JPSS-2 research group, Polypharmacy for psychiatric treatments in Japan.  Lancet. 2002;  360 647
• 26 Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom.  Int J Psychiatry in Clin Practice. 2000;  4 41-46
• 27 Voirol P, Robert P -A, Meister P, Oros L, Baumann P. Psychotropic drug prescription in a psychiatric university hospital.  Pharmacopsychiatry. 1999;  32 29-37